NCT04199806

Brief Summary

To collect data from Allergan Patient Surveys (patient surveys) and Allergan Patient Information Form (patient information form) to describe:

  1. 1.Patient demographics
  2. 2.Treatment patterns
  3. 3.Patient feedback and overall experience with MMS treatment

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Nov 2019

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 22, 2019

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

December 3, 2019

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 16, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2020

Completed
Last Updated

December 16, 2019

Status Verified

December 1, 2019

Enrollment Period

6 months

First QC Date

December 3, 2019

Last Update Submit

December 12, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy Endpoint: Overall Experience Questionnaire

    Evaluation of patient overall experience with MMS treatment as measured by patient survey.

    Immediately post subjects final treatment.

Study Arms (1)

Questionnaire Review

OTHER
Other: Questionnaire review

Interventions

Review data from questionnaires received about MMS experience.

Questionnaire Review

Eligibility Criteria

Age22 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has received MMS treatment in the abdomen and/or buttocks (with CoolTone prototype)
  • Subject has completed the Allergan patient survey and information form on MMS experience between July 1, 2019 and December 1, 2019.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Kerrie Jiang, NP

    Zeltiq Aesthetics

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2019

First Posted

December 16, 2019

Study Start

November 22, 2019

Primary Completion

June 1, 2020

Study Completion

June 1, 2020

Last Updated

December 16, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share